Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
about
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Homologous recombination defic ...... tion-associated breast cancer.
@en
type
label
Homologous recombination defic ...... tion-associated breast cancer.
@en
prefLabel
Homologous recombination defic ...... tion-associated breast cancer.
@en
P2093
P2860
P1476
Homologous recombination defic ...... ation-associated breast cancer
@en
P2093
Alexander Gutin
Anne-Renee Hartman
Chris Neff
Elisha Hughes
Jessica Hellyer
Joshua Jones
Kirsten M Timms
Kristin C Jensen
Pei-Jen Chang
Rebecca N Peterson
P2860
P2888
P304
P356
10.1007/S10549-017-4624-7
P407
P577
2017-12-23T00:00:00Z